Vivos Therapeutics cost-cutting measures pay off in 2Q

Vivos Therapeutics (NASDAQ:VVOS) said its cost-cutting initiatives drove a significant reduction in its net loss during the second quarter when compared to...

Related Keywords

Kirk Huntsman ,Drug Administration ,Vivos Institute ,Vivos Therapeutics ,Vivos Integrated Provider ,